Octane

Octane

SCHEMBL7318447

CCCCCCCC.O=C(O)C(=O)O

nearest known ligand 0.63

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Octane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR84 Q9NQS5 7/20 0.63
PPARG P37231 7/20 0.63
PPARD Q03181 7/20 0.63
PPARA Q07869 7/20 0.63
HDAC11 Q96DB2 5/20 0.63
TSHR P16473 5/20 0.63
PTPN1 P18031 3/20 0.63
ALDH1A1 P00352 2/20 0.63
TLR2 O60603 2/20 0.63
TDP1 Q9NUW8 2/20 0.63
FABP4 P15090 2/20 0.63
SLC22A6 Q4U2R8 1/20 0.63
SLC22A8 Q8TCC7 1/20 0.63
MEN1 O00255 1/20 0.63
ESR1 P03372 1/20 0.63
ALOX15 P16050 1/20 0.63
PDE4A P27815 1/20 0.63
KMT2A Q03164 1/20 0.63
PDE3A Q14432 1/20 0.63
HSD17B10 Q99714 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL29374141 1.00 GPR84 (0.63) GPR84PPARGPPARDPPARAHDAC11
Octane SCHEMBL27319833 1.00 GPR84 (0.63) GPR84PPARGPPARDPPARAHDAC11
Dodecane SCHEMBL27664718 1.00 GPR84 (0.63) GPR84PPARGPPARDPPARAHDAC11
Nonane SCHEMBL30314239 1.00 GPR84 (0.63) GPR84PPARGPPARDPPARAHDAC11
Nonane SCHEMBL20424067 1.00 GPR84 (0.63) GPR84PPARGPPARDPPARAHDAC11
Decane SCHEMBL9082736 1.00 GPR84 (0.63) GPR84PPARGPPARDPPARAHDAC11
Heptane SCHEMBL8495878 1.00 GPR84 (0.63) GPR84PPARGPPARDPPARAHDAC11
Heptane SCHEMBL29366051 1.00 GPR84 (0.63) GPR84PPARGPPARDPPARAHDAC11
Octane SCHEMBL29554931 1.00 GPR84 (0.63) GPR84PPARGPPARDPPARAHDAC11
Octane SCHEMBL8643421 0.97 GPR84 (0.60) GPR84PPARGPPARDPPARAHDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0790995-A1 A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS NOVO NORDISK A/S (DK) 1997-08-27 EP claimed
EP-0714394-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1996-06-05 EP claimed
WO-1995005379-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO claimed
CN-118019742-A Novel benzodiazepine derivatives as GABA Aγ1 PAM 豪夫迈·罗氏有限公司 2024-05-10 CN disclosed
US-20240140967-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF LEO PHARMA A/S (DK) 2024-05-02 US disclosed
CN-117865992-A Process for preparing 7H-pyrrolo [2,3-d ] pyrimidine derivatives and synthetic intermediates therefor 日本烟草产业株式会社 2024-04-12 CN disclosed
CN-110300756-B Process for preparing 7H-pyrrolo [2,3-d ] pyrimidine derivatives and synthetic intermediates therefor 日本烟草产业株式会社 2024-01-02 CN disclosed
CN-116802184-A Pyrazolothiazole carboxamides and their use as PDGFR inhibitors 埃科特莱茵药品有限公司 2023-09-22 CN disclosed
CN-109651358-B 4-aminopyridine derivative, pharmaceutical composition, preparation method and application thereof 上海迪诺医药科技有限公司 2023-04-07 CN disclosed
CN-111704615-B Imidazo [1,5-A ] pyrazine derivatives as PI3Kdelta inhibitors 百济神州有限公司 2023-02-17 CN disclosed
CN-115697993-A Pyrimidines as AXL inhibitors 南京正大天晴制药有限公司 2023-02-03 CN disclosed
CN-1121349-A Heterocyclic compounds and their preparation and use NOVO NORDISK AS (DK) 1996-04-24 CN disclosed
US-5510374-A USEFUL IN TREATMENT OF DISORDERS OF THE SEROTINERGIC SYSTEM ADIR ET COMPAGNIE (FR) 1996-04-23 US disclosed
EP-0287356-B1 Bridgehead substituted azabicyclic derivatives BEECHAM GROUP PLC (GB) 1996-01-24 EP disclosed
EP-0687266-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1995-12-20 EP disclosed
WO-1995017180-A1 A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS NOVO NORDISK A/S (DK) 1995-06-29 WO disclosed
WO-1995005379-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO disclosed
WO-1994020496-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-09-15 WO disclosed
EP-0328200-B1 Five-membered ring systems with bonded azacyclic ring substituents MERCK SHARP & DOHME (GB) 1993-12-08 EP disclosed
US-5041456-A Pharmaceutically useful 3-(indol-3-yl)-1,2,4-oxa- and thiadiazoles substituted in the 5-position by an amino containing group MERCK SHARP & DOHME LTD. (GB) 1991-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240140967-A1 PROCESS FOR PREPARING 7H-PYRROLO[2,3-d]PYRIMIDINE DERIVATIVES AND SYNTHETIC INTERMEDIATES THEREOF JAK1, JAK3, JAK2 GPR84 3548/4885PPARG 2087/4885PPARD 1080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.